Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119494 | 0.99 | ALDH1A1 (0.54) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL26603989 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL24113875 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL26603994 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL16171455 | 0.86 | ALDH1A1 (0.53) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL17439173 | 0.86 | ALDH1A1 (0.53) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL7860220 | 0.86 | SIGMAR1 (0.52) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL21240870 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL31696971 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL25937663 | 0.84 | ACHE (0.55) | ALDH1A1KDM4EMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317687-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | CYTOKINETICS, INC. | 2024-09-26 | — | — | US | claimed |
| US-11958809-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2024-04-16 | — | — | US | claimed |
| US-20220153700-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | CYTOKINETICS, INC. | 2022-05-19 | — | — | US | claimed |
| US-12583821-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-2970123-B2 | CRYSTALLINE DIHYDROCHLORIDE HYDRATE SALT OF OMECAMTIV MECARBIL AND PROCESS FOR ITS PREPARATION | AMGEN INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250243163-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | AMGEN INC. | 2025-07-31 | — | — | US | disclosed |
| US-12275704-B2 | Heterocyclic compounds and their uses | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12221417-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240317687-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | CYTOKINETICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240217933-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2024-07-04 | — | — | US | disclosed |
| US-11958809-B2 | Salt of omecamtiv mecarbil and process for preparing salt | CYTOKINETICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-2968180-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180312469-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | CYTOKINETICS, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20180273479-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CYTOKINETICS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-9988354-B2 | Salt of omecamtiv mecarbil and process for preparing salt | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9951015-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9895308-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160015628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CYTOKINETICS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160016906-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | AMGEN INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20140309235-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CYTOKINETICS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | SI, MLN, MLNR | ACHE 524/4885ALDH1A1 1507/4885KDM4E 1057/4885 |
| US-20250243163-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | SI, SLC5A6, SLC28A1 | ACHE 3312/4885ALDH1A1 1835/4885KDM4E 563/4885 |
| US-20180273479-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | SI, MLN, MLNR | ACHE 524/4885ALDH1A1 1507/4885KDM4E 1057/4885 |
| US-20220153700-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | SI, SLC5A6, SLC28A1 | ACHE 3312/4885ALDH1A1 1835/4885KDM4E 563/4885 |
| US-20240317687-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | SI, SLC5A6, SLC28A1 | ACHE 3312/4885ALDH1A1 1835/4885KDM4E 563/4885 |
| US-20140309235-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | SI, MLN, MLNR | ACHE 524/4885ALDH1A1 1507/4885KDM4E 1057/4885 |
| US-12275704-B2 | Heterocyclic compounds and their uses | SI, MLN, MLNR | ACHE 524/4885ALDH1A1 1507/4885KDM4E 1057/4885 |
| US-20180312469-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | SI, SLC5A6, SLC28A1 | ACHE 3312/4885ALDH1A1 1835/4885KDM4E 563/4885 |
| US-12583821-B2 | Salt of omecamtiv mecarbil and process for preparing salt | SLC28A2, SLC28A1, SLC5A11 | ACHE 1380/4885ALDH1A1 1521/4885KDM4E 277/4885 |
| US-20240217933-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | SI, MLN, MLNR | ACHE 524/4885ALDH1A1 1507/4885KDM4E 1057/4885 |
| US-11958809-B2 | Salt of omecamtiv mecarbil and process for preparing salt | SI, SLC5A6, SLC28A1 | ACHE 3312/4885ALDH1A1 1835/4885KDM4E 563/4885 |
| US-12221417-B2 | Salt of omecamtiv mecarbil and process for preparing salt | SI, SLC5A6, SLC28A1 | ACHE 3312/4885ALDH1A1 1835/4885KDM4E 563/4885 |
| US-20160016906-A1 | SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT | SI, AREG, CA12 | ACHE 1336/4885ALDH1A1 2291/4885KDM4E 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.